Picture of Biofrontera AG logo

B8F Biofrontera AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

REG - Biofrontera AG - Total Voting Rights <Origin Href="QuoteRef">B8FGn.DE</Origin>

RNS Number : 6019K
Biofrontera AG
31 December 2015

31 December 2015

Biofrontera AG

("Biofrontera" or the "Company")

Total Voting Rights

Leverkusen, 31 December 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on sun induced skin cancer, announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 25,490,430 ordinary shares of no par value each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is therefore 25,490,430.

The above figure of 25,490,430 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.

Enquiries, please contact:

Biofrontera AG

Prof. Hermann Lbbert, Chief Executive Officer

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0

press@biofrontera.com

www.biofrontera.com

IR Germany: Brainwell Asset Solutions

Jrgen Benker

+49 (0) 152 08931514

Nomad and Broker: Shore Capital

Bidhi Bhoma / Toby Gibbs

+44(0) 20 7408 4090

IR UK: Seton Services

Toni Vallen

+44(0) 20 7603 6797

Financial PR: Gable Communications

John Bick / Justine James

+44(0) 20 7193 7463

+44 (0)7872 061007

Background:

Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos dermatological range of cosmetics. Belixos products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lbbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.


This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRFDIFFFFISEIE

Recent news on Biofrontera AG

See all news